8.52
+0.12(+1.43%)
Currency In USD
| Previous Close | 8.4 |
| Open | 8.34 |
| Day High | 8.76 |
| Day Low | 8.19 |
| 52-Week High | 11.54 |
| 52-Week Low | 2.86 |
| Volume | 612,147 |
| Average Volume | 1.19M |
| Market Cap | 584.98M |
| PE | -4.84 |
| EPS | -1.76 |
| Moving Average 50 Days | 8.91 |
| Moving Average 200 Days | 5.8 |
| Change | 0.12 |
If you invested $1000 in Olema Pharmaceuticals, Inc. (OLMA) since IPO date, it would be worth $172 as of November 17, 2025 at a share price of $8.428. Whereas If you bought $1000 worth of Olema Pharmaceuticals, Inc. (OLMA) shares 3 years ago, it would be worth $3,121.56 as of November 17, 2025 at a share price of $8.428.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Olema Oncology Reports Third Quarter 2025 Financial and Operating Results
GlobeNewswire Inc.
Nov 10, 2025 12:00 PM GMT
Announced new clinical trial agreement with Pfizer to evaluate palazestrant in combination with atirmociclib in ER+/HER2- metastatic breast cancerInitiated OPERA-02 Phase 3 trial of palazestrant in combination with ribociclib in frontline ER+/HER2- m
Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025
GlobeNewswire Inc.
Oct 30, 2025 8:30 PM GMT
SAN FRANCISCO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies
Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025
GlobeNewswire Inc.
Oct 18, 2025 7:00 AM GMT
Palazestrant in combination with ribociclib demonstrated encouraging activity across all dose cohorts and subgroups Median PFS was 15.5 months in the 120 mg palazestrant cohort across all patientsIn the 120 mg palazestrant cohort among patients with